

## REFERENCES

1. Marcus DM, Goodman M, Jani AB, Osunkoya AO, Rossi PJ. A Comprehensive Review of Incidence and Survival in Patients with Rare Histological Variants of Prostate Cancer in the United States from 1973 to 2008. *Prostate Cancer Prostatic Diseases* 2012;15:283-8.
2. Wang W, Epstein JI. Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases. *American Journal of Surgical Pathology* 2008;32:65-71.
3. Yashi M, Terauhi F, Nukui A, Ochi M, Yuzawa M, Hara Y et al. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: A case report and short literature review. *Urol Oncol* 2006;24:313-7.
4. Deorah S, Rao MB, Raman R, Gaitonde K, Donovan JF. Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study. *BJU Int* 2012;109:824-30.
5. Abbas F, Civantos F, Benedetto F, Soloway MS. Small cell carcinoma of the bladder and prostate. *Urology* 1995; 46:617-630.
6. Wenk RE, Bhagavan BS, Levy R. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. *Cancer* 1977;40:773-8.
7. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. *Journal of Urology* 1992;147:804-7.
8. Tetu B, Ro JY, Ayala AG, Ordonez NG, Logothetis CJ, Von Eschenbach AC. Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome. *Urology* 1989;33:148-152.
9. Van Bokhoven A, Varella-Garcia M, Korch C. Molecular characterization of human prostate carcinoma cell lines. *Prostate* 2003;57:205-25
10. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, et al. Neuroendocrine Prostate Cancer Xenografts with Large-Cell and Small-Cell Features Derived from a Single Patient's Tumor: Morphological, Immunohistochemical, and Gene Expression Profiles. *The Prostate* 2011;71:846-56.
11. Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O, et al. Progression of prostate cancer to neuroendocrine cell tumor. *Int J Urol* 2001;8:431-6.
12. Aprikian AG, Cordon-Cardo C, Fair WC, Zhang ZF, Bazinet M, Hamdy SM, et al. Neuroendocrine Differentiation in Metastatic Prostatic Adenocarcinoma. *The Journal of Urology* 1994;151:914-9.
13. Rubenstein JH, Katin MJ, Mangano MM, Dauphin J, Salenius SA, Dosoretz DE, et al. Small cell anaplastic carcinoma of the prostate: Seven new cases, review of the literature and discussion of a therapeutic strategy. *Am J Clin Onc* 1997;20:376-80.
14. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. *J Urol* 1992; 147:935-7.
15. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. *Clin Cancer Res* 2013;19:3621-30.